SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/forms-1a.htm

Chunk 14 of 85
Word Count: 1417
Character Count: 9597

Document Content:

includes an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going concern. If we are unable to raise sufficient capital when needed, our business, financial condition and results of operations will be materially and adversely affected, and we will need to significantly modify our operational plans to continue as a going concern. If we are unable to continue as a going concern, we might have to liquidate our assets and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements. The inclusion of a going concern explanatory paragraph by our auditors, our lack of cash resources and our potential inability to continue as a going concern may materially adversely affect our share price and our ability to raise new capital or to enter into critical contractual relations with third parties.

are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and
retain personnel necessary for our success.

are highly dependent on our senior management and other key personnel. Our success will depend on our ability to retain senior management
and to attract and retain qualified personnel in the future, including sales and marketing professionals, scientists, clinical specialists,
engineers and other highly skilled personnel and to integrate current and additional personnel in all departments. The loss of members
of our senior management, sales and marketing professionals, scientists, clinical and regulatory specialists and engineers could result
in delays in product development and harm our business. If we are not successful in attracting and retaining highly qualified personnel,
it would have a material adverse effect on our business, financial condition and results of operations.

Competition
for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable
terms, or at all. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have issued stock
options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in
our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies.
Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment
with us on short notice. Our employment arrangements with our employees provide for at-will employment, which means that any of our employees
could leave our employment at any time, with or without notice. We also do not maintain “key man” insurance policies on the
lives of these individuals or the lives of any of our other employees.

David
Richmond, our Co-Chief Executive Officer and Chief Financial Officer, also holds certain management positions and directorships of other
companies and may allocate his time to such other businesses, thereby causing conflicts of interest in his determination as to how much
time to devote to our affairs. This could have a negative impact on our ability to implement our plan of operation.

David
Richmond, our Co-Chief Executive Officer and Chief Financial Officer, is engaged in other business endeavors for which he may be entitled
to compensation, which may result in a conflict of interest in allocating his time between our operations and his other businesses. Pursuant
to Mr. Richmond’s employment agreement that will be effective as of the consummation of this offering, Mr. Richmond shall be employed
with us on a full-time basis, but shall be permitted to participate in certain limited business activities, including serving
on boards, committees or similar bodies of charitable or nonprofit organizations (subject to prior written approval from the board of
directors), fulfilling limited teaching, speaking and writing engagements (subject to prior written approval from the board of directors),
and managing his personal investments, in each case, so long as such activities do not individually or in the aggregate materially interfere
or conflict with the performance of Mr. Richmond’s duties and responsibilities under his employment agreement. Accordingly, although
Mr. Richmond is employed with our company on a full-time basis, he may hold certain management positions and directorships of other companies,
and may allocate his time to such other businesses, thereby causing conflicts of interest in his determination as to how much time to
devote to our affairs.

Richmond may also have competitive fiduciary obligations and pecuniary interests relating to his other business ventures that conflict
with our interests. Mr. Richmond’s employment agreement contains certain restrictive covenants while they are employed by us. These
restrictive covenants, generally, restrict Mr. Richmond from engaging in any other activities that materially interfere with or
conflict with the performance of Mr. Richmond’s duties and responsibilities under his employment agreement. Mr. Richmond is further
subject to general restrictions regarding the use or disclosure of any confidential information, of our business.
Notwithstanding the foregoing, to the extent that these additional activities may have a conflict between their interests and ours, this
could have a negative impact on our ability to implement our plan of operations.

Our management team has limited
experience operating a public company, which may require additional time and resources as we transition to public company reporting and
governance requirements.

Our current management
team has not previously operated a public company and therefore has limited experience with public company accounting, reporting, compliance,
and governance processes and procedures. In particular, while we have strengthened our finance organization by hiring accounting and
financial reporting personnel with significant public company and technical accounting experience and by engaging experienced external
advisors, our Chief Financial Officer does not have direct experience with the ongoing requirements of operating as a public company.

We are continuing
to enhance our internal controls, systems, and reporting processes to meet public company standards. However, we cannot assure you that
these efforts will be sufficient to prevent delays, errors, or increased costs associated with public company compliance. Any failure
to effectively transition to public company operations could adversely affect our business, financial condition, and stock price.

intend to expand sales of any approved product candidates internationally in the future, but we may experience difficulties in obtaining
regulatory clearance or approval in the United States or in successfully marketing our product candidates internationally even if approved.
A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.

While
we believe that if the Revivent System receives FDA approval, most of our revenue will be generated in the United States, we intend
to increase our sales outside the United States as well, including the EU, where we have obtained a CE Mark. Currently, other than through an authorized U.S. clinical site, the Revivent System is only available outside the United States. Sales of our product candidates outside of the United States are and will be subject
to foreign regulatory requirements governing clinical trials and marketing approval. We will incur substantial expenses in connection
with our international expansion. Additional risks related to operating in foreign countries include:

●	differing
regulatory requirements in foreign countries;

●	differing
reimbursement regimes in foreign countries, including price controls;

●	unexpected
changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;

●	economic
weakness, including inflation, or political instability in particular foreign economies and markets;

●	compliance
with tax, employment, immigration and labor laws for employees living or traveling abroad;

●	foreign
taxes, including withholding of payroll taxes;

●	foreign
currency fluctuations, which could result in increased operating expenses, reduced revenue and other obligations incident to doing
business in another country;

●	difficulties
staffing and managing foreign operations;

●	workforce
uncertainty in countries where labor unrest is more common than in the United States;

●	potential
liability under the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), or comparable foreign regulations;

●	challenges
enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect
intellectual property rights to the same extent as the United States;

●	product
shortages resulting from any events affecting raw material or finished good supply or distribution or manufacturing capabilities
abroad; and

●	business
interruptions resulting from geopolitical actions, including war and terrorism.

These
and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable
operations, which would have a material adverse effect on our business, financial condition and results of operations.